Anti Cancer Drugs

Product Details:

Tagrisso (Osimertinib 40mg) Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.
Tagrisso 40mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Uses Of Tagrisso Tablet:
Non-small cell lung cancer.

Benefits Of Tagrisso Tablet:
In Non-small cell lung cancerNon-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Tagrisso 40mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

Side Effects Of Tagrisso Tablet:
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them Common side effects of Tagrisso Diarrhea Loss of appetite Rash Stomatitis (Inflammation of the mouth).

How To Use Tagrisso Tablet:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Tagrisso 40mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

How Tagrisso Tablet Works:
Tagrisso 40mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Safety Advice:

• It is not known whether it is safe to consume alcohol with Tagrisso 40mg Tablet. 
• Tagrisso 40mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. 
• Tagrisso 40mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
• Tagrisso 40mg Tablet does not usually affect your ability to drive.
• Tagrisso 40mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Tagrisso 40mg Tablet is recommended.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Ibrunat 140 mg Uses
Ibrunat is kind of a medicine which is prescribed for treating adult patients who has the following types of blood cancers:

• Mantle cell lymphoma
• Waldenstrom’s macroglobulinemia
• Chronic Graft Versus Host Disease
• Chronic lymphocytic leukemia and
• Marginal zone lymphoma (MZL)
• Small Lymphocytic Lymphoma

Product Details:

LENVIMA (lenvatinib 4mg 10mg) is a prescription medicine that is used to treat certain kinds of cancer.
LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingLENVIMA is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineLENVIMA is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if LENVIMA is safe and effective in children.
IMPORTANT SAFETY INFORMATIONLENVIMA may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of LENVIMA and can be serious. Your blood pressure should be well controlled before you start taking LENVIMA. Your healthcare provider should check your blood pressure regularly during treatment with LENVIMA. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: LENVIMA can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: LENVIMA may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with LENVIMA. Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with LENVIMA treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of LENVIMA and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with LENVIMA
diarrhea: Diarrhea is a common side effect of LENVIMA and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with LENVIMA to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG
low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with LENVIMA and may tell you to take a calcium supplement if your calcium levels are low.

Product Details:

BDFOIE (Lenvatinib 4mg ,10mg) is a prescription medicine that is used to treat certain kinds of cancer.
BDFOIE is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingBDFOIE is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineBDFOIE is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if BDFOIE is safe and effective in children.
IMPORTANT SAFETY INFORMATIONBDFOIE may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of BDFOIE and can be serious. Your blood pressure should be well controlled before you start taking BDFOIE. Your healthcare provider should check your blood pressure regularly during treatment with BDFOIE. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: BDFOIE can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: BDFOIE may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with BDFOIE. Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with BDFOIE treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of BDFOIE and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with BDFOIE
diarrhea: Diarrhea is a common side effect of BDFOIE and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with BDFOIE to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG
low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with BDFOIE and may tell you to take a calcium supplement if your calcium levels are low.

Additional Information:

• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

LYNPARZA (Olaparib 150mg) is a prescription medicine used to treat adults who have:
advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. LYNPARZA is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youadvanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. LYNPARZA is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. LYNPARZA is used after the cancer has responded to treatment with platinum-based chemotherapyadvanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youa certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for youmetastatic pancreatic cancer with a certain type of abnormal inherited BRCA gene. LYNPARZA is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure LYNPARZA is right for youprostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes). LYNPARZA is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure LYNPARZA is right for youIt is not known if LYNPARZA is safe and effective in children.IMPORTANT SAFETY INFORMATION LYNPARZA may cause serious side effects, including:Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:before treatment with LYNPARZAevery month during treatment with LYNPARZA (Olaparib 150mg)weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve.

Product Details:

Osimertinib 40mg Tablet is a protein kinase inhibitor used in the treatment of non-small cell lung cancer. It is used in the treatment of adult patients who have certain estimated glomerular filtration rate (EGFR) mutations.
Osimertinib 40mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Diarrhea is very common side effect of this medicine, so drink plenty of fluids. But, you must inform your doctor if it does not stop. You must have to inform your doctor if you experience difficulty in breathing along with fever and cough, or severe peeling of the skin. This medicine may reduce the number of blood cells (decrease white blood cells) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells.
Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Uses Of Tagrisso Tablet:
Non-small cell lung cancer

Benefits Of Tagrisso Tablet:
In Non-small cell lung cancerNon-small cell lung cancer is one of the major kinds of lung cancer and it affects both smokers as well as non-smokers. Osimertinib 40mg Tablet helps treat non-small cell lung cancer and may be given alone or in combination with other medicines. It is a potent and very toxic medicine and you should discuss the risks and benefits with your doctor. You should avoid drinking alcohol while having this treatment and drink plenty of water to stay hydrated.

Side Effects Of Tagrisso Tablet:
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of TagrissoDiarrheaLoss of appetiteRashStomatitis (Inflammation of the mouth).

How To Use Tagrisso Tablet:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Osimertinib 40mg Tablet may be taken with or without food, but it is better to take it at a fixed time.

How Tagrisso Tablet Works:
Osimertinib 40mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Safety Advice:

• It is not known whether it is safe to consume alcohol with Osimertinib 40mg Tablet. 
• Osimertinib 40mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. 
• Osimertinib 40mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
• Osimertinib 40mg Tablet does not usually affect your ability to drive.
• Osimertinib 40mg Tablet is safe to use in patients with kidney disease. No dose adjustment of Osimertinib 40mg Tablet is recommended.

Product Details:

Alpelisib 300mg tablets is contraindicated in patients with severe hypersensitivity to it or any of its components Indication
PIQRAY® (alpelisib) tablets is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

Important Safety Information
Alpelisib is contraindicated in patients with severe hypersensitivity to it or any of its components.

Severe Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, can occur in patients treated with PIQRAY. Severe hypersensitivity reactions were manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever, or tachycardia. The incidence of grade 3 and 4 hypersensitivity reactions was 0.7%. Advise patients of the signs and symptoms of severe hypersensitivity reactions. Permanently discontinue Alpelisib in the event of severe hypersensitivity.
Severe Cutaneous Adverse Reactions (SCARs): SCARs including Stevens-Johnson syndrome (SJS), erythema multiforme (EM), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) can occur in patients treated with PIQRAY. In the SOLAR-1 study, SJS and EM were reported in 0.4% and 1.1% of patients, respectively. DRESS was reported in patients in the postmarketing setting. If signs or symptoms of SCARs occur, interrupt Alpelisib until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended.

If a SCAR is confirmed, permanently discontinue PIQRAY. Do not reintroduce Alpelisib in patients who have experienced previous SCARs during Alpelisib treatment. If it is not confirmed, Alpelisib may require dose modifications, topical corticosteroids, or oral antihistamine treatment.
Advise patients of the signs and symptoms of SCARs (eg, a prodrome of fever, flu-like symptoms, mucosal lesions, progressive skin rash, or lymphadenopathy).
Hyperglycemia: Severe hyperglycemia, including ketoacidosis, can occur in patients treated with PIQRAY. Hyperglycemia was reported in 65% of patients treated with PIQRAY. Grade 3 (FPG >250-500 mg/dL) and grade 4 (FPG >500 mg/dL) hyperglycemia were reported in 33% and 3.9% of patients, respectively. Ketoacidosis was reported in 0.7% of patients (n=2) treated with PIQRAY.

Before initiating treatment with PIQRAY, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. After initiating treatment with PIQRAY, monitor fasting glucose (FPG or fasting blood glucose) at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated. Monitor HbA1c every 3 months and as clinically indicated. If a patient experiences hyperglycemia after initiating treatment with PIQRAY, monitor fasting glucose as clinically indicated, and at least twice weekly until fasting glucose decreases to normal levels. During treatment with antidiabetic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks and as clinically indicated. Consider consultation with a health care practitioner with expertise in the treatment of hyperglycemia and counsel patients on lifestyle changes.

The safety of Alpelisib in patients with type 1 and uncontrolled type 2 diabetes has not been established as these patients were excluded from the SOLAR-1 trial. Patients with a medical history of type 2 diabetes were included. Patients with a history of diabetes mellitus may require intensified diabetic treatment. Closely monitor patients with diabetes.

Product Details:

VITRAKVI (Larotrectinib 25mg )is a prescription medicine that is used to treat adults and children with solid tumors (cancer) that: are caused by certain abnormal NTRK genes and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatment. Your healthcare provider will perform a test to make sure that VITRAKVI is right for you. It is not known if VITRAKVI is safe and effective in children younger than 1 month of age. What are the possible side effects of VITRAKVI? VITRAKVI may cause serious side effects, including: Nervous system problems. Tell your healthcare provider if you develop any symptoms such as confusion, difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensation in your hands and feet. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop VITRAKVI if you develop symptoms of a nervous system problem with VITRAKVI. Liver problems. Your healthcare provider will do blood tests to check your liver function during treatment with VITRAKVI. Tell your healthcare provider right away if you develop symptoms of liver problems including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop VITRAKVI if you develop liver problems with VITRAKVI. The most common side effects of VITRAKVI include: tiredness nausea dizziness vomiting cough constipation diarrhea VITRAKVI may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects with VITRAKVI. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. DESCRIPTION Larotrectinib is a kinase inhibitor. VITRAKVI (larotrectinib) capsules and oral solution are formulated using larotrectinib sulfate. The molecular formula for larotrectinib sulfate is C21H24F2N6O6S and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for the free base. The chemical name is (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate. Larotrectinib sulfate has the following chemical structure: VITRAKVI® (larotrectinib) Structural Formula - Illustration Larotrectinib sulfate is an off-white to pinkish yellow solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according to USP descriptive terms of solubility). VITRAKVI (larotrectinib) capsules and oral solution are for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and 123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The capsule is composed of gelatin, titanium dioxide, and edible ink. The oral solution contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.

Product Details:

Larotrectinib 25mgis a prescription medicine that is used to treat adults and children with solid tumors (cancer) that:  are caused by certain abnormal NTRK genes and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatment. Your healthcare provider will perform a test to make sure that Larotrectinib is right for you.  It is not known if Larotrectinib is safe and effective in children younger than 1 month of age.  What are the possible side effects of Larotrectinib?  Larotrectinib may cause serious side effects, including:  Nervous system problems. Tell your healthcare provider if you develop any symptoms such as confusion, difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensation in your hands and feet. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Larotrectinib if you develop symptoms of a nervous system problem with Larotrectinib. Liver problems. Your healthcare provider will do blood tests to check your liver function during treatment with Larotrectinib. Tell your healthcare provider right away if you develop symptoms of liver problems including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Larotrectinib if you develop liver problems with Larotrectinib. The most common side effects of Larotrectinib include:  tiredness nausea dizziness vomiting cough constipation diarrhea Larotrectinib may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you.  These are not all the possible side effects with Larotrectinib. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.  DESCRIPTION Larotrectinib is a kinase inhibitor. Larotrectinib (larotrectinib) capsules and oral solution are formulated using larotrectinib sulfate. The molecular formula for larotrectinib sulfate is C21H24F2N6O6S and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for the free base. The chemical name is (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate. Larotrectinib sulfate has the following chemical structure:  Larotrectinib® (larotrectinib) Structural Formula - Illustration Larotrectinib sulfate is an off-white to pinkish yellow solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according to USP descriptive terms of solubility).  Larotrectinib (larotrectinib) capsules and oral solution are for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and 123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The capsule is composed of gelatin, titanium dioxide, and edible ink.  The oral solution contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

LARTRUVO (Olaratumab 10mg)is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. This indication is approved under accelerated approval [see Clinical Studies]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. DOSAGE AND ADMINISTRATION Recommended Dosage The recommended dose of LARTRUVO is 15 mg/kg administered as an intravenous infusion over 60 minutes on Days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity. For the first 8 cycles, LARTRUVO is administered with doxorubicin, [see Clinical Studies]. Refer to doxorubicin prescribing information for dosing, and dose modifications. Premedication Premedicate with diphenhydramine (25 to 50 mg intravenously) and dexamethasone (10 to 20 mg intravenously) prior to LARTRUVO on Day 1 of cycle 1. Dosing Modifications Infusion-Related Reactions Permanently discontinue LARTRUVO for Grade 3 or 4 infusion-related reactions [see Premedication and WARNINGS AND PRECAUTIONS]. Interrupt infusion of LARTRUVO for Grade 1 or 2 infusion-related reactions (IRR). After resolution, resume LARTRUVO infusion at 50% of the initial infusion rate. [see WARNINGS AND PRECAUTIONS] Neutropenia For neutropenic fever/infection or Grade 4 neutropenia lasting longer than 1 week, discontinue administration of LARTRUVO until the absolute neutrophil count is 1,000 /microliter or greater and then permanently reduce the dose to 12 mg/kg. Preparation And Administration Preparation Inspect vial contents for particulate matter and discoloration prior to dilution [see DESCRIPTION]. Discard the vial if particulate matter or discolorations are identified. Withdraw calculated dose and further dilute with 0.9% Sodium Chloride Injection, USP to a final volume of 250 mL for intravenous infusion. Do not use dextrose-containing or other solutions. Gently invert but do not shake. DO NOT FREEZE the diluted solution. Store the diluted solution for up to 24 hours under refrigeration at 2°C to 8°C (36°F to 46°F) and for up to an additional 4 hours at room temperature (below 25°C [77°F]). Storage times include the duration of infusion. If refrigerated, allow the diluted solution to come to room temperature prior to administration. Discard vial with any unused portion of LARTRUVO. Administration Do not administer LARTRUVO as an intravenous push or bolus. Do not co-infuse with electrolytes or other medications through the same intravenous line. Visually inspect the diluted solution for particulate matter and discoloration prior to administration. If particulate matter or discolorations are identified, discard the solution. Administer diluted solution as an intravenous infusion over 60 minutes. Flush the line with 0.9% Sodium Chloride Injection, USP at end of infusion. HOW SUPPLIED Dosage Forms And Strengths Injection: 500 mg/50 mL (10 mg/mL) or 190 mg/19 mL (10 mg/mL) clear to slightly opalescent, colorless to slightly yellow solution in a single-dose vial.

Product Details:

Kryxana (Ribociclib 200mg)  Tablet is an anti-cancer medicine used in the treatment of metastatic breast cancer. It helps to slow down the growth of cancer cells and eventually kills them. This way it treats the symptoms of breast cancer such as breast lumps, bloody discharge from nipples, or changes in the shape of the breast.

Kryxana 200mg Tablet may be taken with or without food and usually taken in combination with another medicine. The duration of treatment varies on the basis of your need and response to treatment. Take it in the exact dose and duration prescribed by your doctor. You may be asked for regular blood tests while taking this medication.

Common side effects of this medicine include decreased white blood cell count, nausea, fatigue, diarrhea, hair loss, vomiting, constipation, headache, and back pain. Neutropenia is a well-recognized adverse effect, in which the number of your white blood cells get reduced and your immune system gets weakened. As a result, you may be at greater risk of getting an infection. However, this side effect disappears rapidly once you stop taking the medicine.

Before using this medicine, let your doctor know if you have any preexisting medical conditions. Let your doctor also know about all the medications you are taking. Additionally, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.USES OF KRYXANA TABLET

• Metastatic breast cancer

BENEFITS OF KRYXANA TABLETIn Metastatic breast cancerKryxana 200mg Tablet helps to treat breast cancer and it may be used alone or in combination with other medicines or treatment modalities like chemotherapy. This medicine is used when other medicines have not shown significant improvement and the cancer has spread to other parts as well. It relieves the symptoms of breast cancer such as breast lumps, bloody discharge from nipples or changes in the shape or texture of the breast. Kryxana 200mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. Discuss with your doctor if any of the side effects bother you.SIDE EFFECTS OF KRYXANA TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of Kryxana

• Decreased white blood cell count
• Nausea
• Fatigue
• Diarrhea
• Hair loss
• Vomiting
• Constipation
• Headache
• Back pain

HOW TO USE KRYXANA TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Kryxana 200mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW KRYXANA TABLET WORKSKryxana 200mg Tablet is an anti-cancer medication. It works by blocking proteins (kinases) which are important for the growth and division of cells. This slows the growth of cancer cells and eventually kills them.SAFETY ADVICEAlcoholCONSULT YOUR DOCTORIt is not known whether it is safe to consume alcohol with Kryxana 200mg Tablet. Please consult your doctor.PregnancyCONSULT YOUR DOCTORKryxana 200mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.BreastfeedingCONSULT YOUR DOCTORKryxana 200mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Product Details:

BDPARIB (Rucaparib 200 Mg) tablets are a prescription medicine used in adults for: the maintenance treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer whose cancer has come back and who are in response (complete or partial response) to a platinum-based chemotherapy the treatment of ovarian cancer, fallopian tube cancer, or primary peritoneal cancer who have certain “BRCA” gene mutations, either inherited (germline) or acquired (somatic), and who have been treated with 2 or more chemotherapy medicines for their cancer. Your healthcare provider will perform a test to make sure BDPARIB is right for you. the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone): that has spread to other parts of the body, and has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer. BDPARIB was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of BDPARIB. Your healthcare provider will perform a test to make sure BDPARIB is right for you. It is not known if BDPARIB is safe and effective in children. SELECT IMPORTANT SAFETY INFORMATION What Warnings should I know about BDPARIB? BDPARIB tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with BDPARIB, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with BDPARIB. You should not use BDPARIB if: You are pregnant or plan to become pregnant. BDPARIB can harm your unborn baby and may cause loss of pregnancy (miscarriage). You should not become pregnant during treatment with BDPARIB. If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with BDPARIB. Females who are able to become pregnant should use effective birth control during treatment and for at least 6 months after receiving the last dose of BDPARIB. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant. You are breastfeeding or plan to breastfeed. It is not known if BDPARIB passes into breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of BDPARIB. Talk to your healthcare provider about the best way to feed your baby during this time. If you are a male with a female partner who is pregnant or able to become pregnant. Effective birth control should be used during treatment and for 3 months after the last dose of BDPARIB. Do not donate sperm during use and for 3 months after the last dose of BDPARIB. What other important information should I know about BDPARIB? Your healthcare provider will do blood tests before, and every month during treatment with BDPARIB to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with BDPARIB until your blood cell counts improve. Avoid spending time in sunlight while on BDPARIB since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

Product Details:

Ribociclib 200mg Tablet is an anti-cancer medicine used in the treatment of metastatic breast cancer. It helps to slow down the growth of cancer cells and eventually kills them. This way it treats the symptoms of breast cancer such as breast lumps, bloody discharge from nipples, or changes in the shape of the breast.
Ribociclib 200mg Tablet may be taken with or without food and usually taken in combination with another medicine. The duration of treatment varies on the basis of your need and response to treatment. Take it in the exact dose and duration prescribed by your doctor. You may be asked for regular blood tests while taking this medication.

Common side effects of this medicine include decreased white blood cell count, nausea, fatigue, diarrhea, hair loss, vomiting, constipation, headache, and back pain. Neutropenia is a well-recognized adverse effect, in which the number of your white blood cells get reduced and your immune system gets weakened. As a result, you may be at greater risk of getting an infection. However, this side effect disappears rapidly once you stop taking the medicine.

Before using this medicine, let your doctor know if you have any preexisting medical conditions. Let your doctor also know about all the medications you are taking. Additionally, inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Product Details:

COTELLIC (Cobimetinib 20mg) is a prescription medicine that is used with the medicine ZELBORAF, to treat a type of skin cancer called melanoma: that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene Your healthcare provider will perform a test to make sure that COTELLIC is right for you. It is not known if COTELLIC is safe and effective in children under 18 years of age. Before you take COTELLIC and ZELBORAF, tell your healthcare provider about all of your medical conditions, including if you: have skin problems or history of skin problems, other than melanoma have bleeding problems, any medical conditions and/or on any medications that increase your risk of bleeding have heart problems, including a condition called long QT syndrome have eye problems have liver or kidney problems have muscle problems have had or are planning to receive radiation therapy have been told that you have low blood levels of potassium, calcium, or magnesium are pregnant or plan to become pregnant. COTELLIC and ZELBORAF can harm your unborn baby. Females who are able to become pregnant should use effective birth control during treatment with COTELLIC and ZELBORAF, and for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken later). Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with COTELLIC and ZELBORAF. are breastfeeding or plan to breastfeed. It is not known if COTELLIC or ZELBORAF passes into your breast milk. Do not breastfeed during treatment with COTELLIC and ZELBORAF and for 2 weeks after the final dose of COTELLIC or ZELBORAF (whichever is taken later). Talk to your healthcare provider about the best way to feed your baby during this time. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Certain medicines may affect the blood levels of COTELLIC. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. How should I take COTELLIC and ZELBORAF in combination? Take COTELLIC and ZELBORAF exactly as your healthcare provider tells you. Do not change your dose or stop taking COTELLIC and ZELBORAF unless your healthcare provider tells you to. Take COTELLIC one time a day for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle. Take ZELBORAF every 12 hours for every day in the 28-day cycle (no rest period). Do not crush or chew ZELBORAF tablets. Take COTELLIC and ZELBORAF with or without food. If you vomit after taking your dose of COTELLIC or ZELBORAF, do not take an additional dose. Take your next dose as scheduled. If you miss a dose of COTELLIC, take your next dose as scheduled. If you miss a dose of ZELBORAF, take it as soon as you remember. If it is within 4 hours of your next scheduled dose, just take your next dose at your regular time. Do not make up for the missed dose. If you take too much ZELBORAF, call your healthcare provider or go the nearest hospital emergency room right away. What should I avoid during treatment with COTELLIC and ZELBORAF? Avoid sunlight during treatment with COTELLIC and ZELBORAF. COTELLIC and ZELBORAF can make your skin sensitive to sunlight. You may burn more easily and get severe sunburns. To help protect against sunburn: When you go outside, wear clothes that protect your skin, including your head, face, hands, arms, and legs. Use lip balm and a broad-spectrum sunscreen with SPF 30 or higher. What are the possible side effects of COTELLIC and ZELBORAF?

Product Details:

Lenvakast (Lenvatinib 4mg ,10mg) is a prescription medicine that is used to treat certain kinds of cancer.
Lenvakast is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressingLenvakast is used along with another medicine called everolimus to treat advanced renal cell carcinoma (RCC), a type of kidney cancer, after one course of treatment with another anti-cancer medicineLenvakast is used by itself as the first treatment for a type of liver cancer called hepatocellular carcinoma (HCC) when it cannot be removed by surgeryIt is not known if Lenvakast is safe and effective in children.
IMPORTANT SAFETY INFORMATIONLenvakast may cause serious side effects, including:
high blood pressure (hypertension): High blood pressure is a common side effect of Lenvakast and can be serious. Your blood pressure should be well controlled before you start taking Lenvakast. Your healthcare provider should check your blood pressure regularly during treatment with Lenvakast. If you develop blood pressure problems, your healthcare provider may prescribe medicine to treat your high blood pressure
heart problems: Lenvakast can cause serious heart problems that may lead to death. Call your healthcare provider right away if you get symptoms of heart problems, such as shortness of breath or swelling of your ankles
problem with blood clots in your blood vessels (arteries): Get emergency medical help right away if you get any of the following symptoms: severe chest pain or pressure; pain in your arms, back, neck, or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; sudden severe headache; sudden vision changes
liver problems: Lenvakast may cause liver problems that may lead to liver failure and death. Your healthcare provider will check your liver function before and during treatment with Lenvakast. Tell your healthcare provider right away if you have any of the following symptoms: your skin or the white part of your eyes turns yellow (jaundice); dark “tea-colored” urine; light-colored bowel movements (stools); feeling drowsy, confused or loss of consciousness
kidney problems: Kidney failure, which can lead to death, has happened with Lenvakast treatment. Your healthcare provider should do regular blood tests to check your kidneys
increased protein in your urine (proteinuria): Proteinuria is a common side effect of Lenvakast and can be serious. Your healthcare provider should check your urine for protein before and during your treatment with Lenvakast
diarrhea: Diarrhea is a common side effect of Lenvakast and can be serious. If you get diarrhea, ask your healthcare provider about what medicines you can take to treat your diarrhea. It is important to drink more water when you get diarrhea. Tell your healthcare provider or go to the emergency room, if you are unable to drink enough liquids and your diarrhea is not able to be controlled
an opening in the wall of your stomach or intestines (perforation) or an abnormal connection between two or more body parts (fistula): Get emergency medical help right away if you have severe stomach (abdomen) pain
changes in the electrical activity of your heart called QT prolongation: QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider will do blood tests before and during your treatment with Lenvakast to check the levels of potassium, magnesium, and calcium in your blood, and may check the electrical activity of your heart with an ECG
low levels of blood calcium (hypocalcemia): Your healthcare provider will check your blood calcium levels during treatment with Lenvakast and may tell you to take a calcium supplement if your calcium levels are low.

Additional Information:

• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

ORGOVYX (Relugolix 120 Mg) is a prescription medicine used for the treatment of advanced prostate cancer. It is the only androgen deprivation therapy (ADT) medicine that is not an injection.

Product Details:

Jakavi ( Ruxolitinib 5mg 10mg 20mg) Tablet is used in the treatment of chronic idiopathic myelofibrosis and Polycythemia vera.
Jakavi 5mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Headache, dizziness, low platelet count are some common side effects of this medicine. This medicine may reduce the number of blood cells (decrease red blood) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, kidney and lipid levels.
Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.USES OF JAKAVI TABLETPolycythemia veraChronic idiopathic myelofibrosisBENEFITS OF JAKAVI TABLETIn Polycythemia veraPolycythemia vera is a type of blood cancer that causes excessive production of red blood cells. This may lead to blood clot formation and lead to other serious health issues. Jakavi 5mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.Show MoreSIDE EFFECTS OF JAKAVI TABLETMost side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about themCommon side effects of JakaviHeadacheDizzinessLow blood plateletsAnemia (low number of red blood cells)HOW TO USE JAKAVI TABLETTake this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jakavi 5mg Tablet may be taken with or without food, but it is better to take it at a fixed time.HOW JAKAVI TABLET WORKSJakavi 5mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.SAFETY ADVICEwarningsAlcoholSAFEConsuming alcohol with Jakavi 5mg Tablet does not cause any harmful side effects.warningsPregnancyCONSULT YOUR DOCTORJakavi 5mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.warningsBreastfeedingCONSULT YOUR DOCTORJakavi 5mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.warningsDrivingUNSAFEJakavi 5mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.warningsKidneyCAUTIONJakavi 5mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Jakavi 5mg Tablet may be needed. Please consult your doctor.Use of Jakavi 5mg Tablet is not advised in patients with moderate to severe kidney disease.

Product Details:

Olaparib 150mg is a prescription medicine used to treat adults who have:
advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Olaparib  is used alone as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youadvanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive laboratory tumor test for genomic instability called HRD. Olaparib  is used in combination with another anti-cancer medicine, bevacizumab, as maintenance treatment after the cancer has responded to your first treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youovarian cancer, fallopian tube cancer, or primary peritoneal cancer, as maintenance treatment, when the cancer has come back. Olaparib  is used after the cancer has responded to treatment with platinum-based chemotherapyadvanced ovarian cancer with a certain type of abnormal inherited BRCA gene, and have received treatment with 3 or more prior types of chemotherapy medicines. Your healthcare provider will perform a test to make sure that Olaparib  is right for youa certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that Olaparib  is right for youmetastatic pancreatic cancer with a certain type of abnormal inherited BRCA gene. Olaparib  is used as a maintenance treatment after your cancer has not progressed on at least 16 weeks of treatment with platinum-based chemotherapy. Your healthcare provider will perform a test to make sure Olaparib  is right for youprostate cancer with certain inherited or acquired abnormal genes called homologous recombination repair (HRR genes). Olaparib  is used when the cancer has spread to other parts of the body (metastatic), and no longer responds to a medical or surgical treatment that lowers testosterone, and has progressed after treatment with enzalutamide or abiraterone. Your healthcare provider will perform a test to make sure Olaparib  is right for youIt is not known if Olaparib  is safe and effective in children.

Important Safety Information:
Olaparib  may cause serious side effects, including:Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with Olaparib . MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Olaparib .
Symptoms of low blood cell counts are common during treatment with Olaparib , but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:before treatment with Olaparib every month during treatment with Olaparib 150mgweekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with Olaparib  until your blood cell counts improve.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Jakura (Tofacitinib 5mg)can lower the ability of your immune system to fight infections. Do not start taking Jakura if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking Jakura . These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with Jakura .
Before and after starting Jakura , tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of Jakura /Jakura XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is Jakura 5 mg twice daily or Jakura XR 11 mg one time each day.
Cancer. Jakura may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of Jakura (10 mg twice daily) or Jakura XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken Jakura with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of Jakura /Jakura XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking Jakura and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Jakura can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using Jakura and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.
Changes in certain lab test results. Your doctor should do blood tests to check your white and red blood cells before and while you are taking Jakura . Your doctor should also check certain liver tests. 

Additional Information:

• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Revolade (Eltrombopag 25mg,50mg) Tablet is used to treat low platelet count due to chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C virus (HCV) infection. It is also used to treat severe aplastic anemia. Revolade 50mg Tablet is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. The function of platelets is to help reduce bleeding. Take it in the exact dose and duration as advised by the doctor. You may take it on an empty stomach. This medicine is to be swallowed as a whole. Do not chew, crush or break it. Inform your doctor if you have any known allergies to this medication. The common side effects include nausea, vomiting, diarrhea, upper respiratory tract infection, and urinary tract infection. Let your doctor know if any of these side effects bother you. They may be able able to suggest ways to reduce or treat the symptoms. Before you take this medicine, inform your doctor if you have any preexisting medical conditions. Let your doctor also know about all the other medicines you are taking. Dose adjustments may be required in patients with liver diseases, inform your doctor. USES OF REVOLADE TABLET Low platelet count due to ITP or HCV infection Treatment of Severe Aplastic Anemia BENEFITS OF REVOLADE TABLET In Low platelet count due to ITP or HCV infection Revolade 50mg Tablet is used to increase the number of platelets (cells that help the blood clot) to decrease the risk of bleeding in adults and children 1 year of age and older who have chronic idiopathic thrombocytopenic purpura (ITP, an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood). It is used in patients who have not benefited or cannot be treated with other treatments, including medications or surgery to remove the spleen. Revolade 50mg Tablet is also used to increase the number of platelets in people who have hepatitis C (a viral infection that may damage the liver). It is usually given along with other medicines. Show More SIDE EFFECTS OF REVOLADE TABLET Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them Common side effects of Revolade Nausea Diarrhea Upper respiratory tract infection Vomiting Increased liver enzymes Muscle pain Urinary tract infection HOW TO USE REVOLADE TABLET Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Revolade 50mg Tablet is to be taken empty stomach. HOW REVOLADE TABLET WORKS Revolade 50mg Tablet is a thrombopoietin agonist. It works by stimulating the formation of new platelets in the blood. Platelets help to reduce or prevent bleeding. SAFETY ADVICE warnings Alcohol CONSULT YOUR DOCTOR It is not known whether it is safe to consume alcohol with Revolade 50mg Tablet. Please consult your doctor. warnings Pregnancy CONSULT YOUR DOCTOR Revolade 50mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor. warnings Breastfeeding CONSULT YOUR DOCTOR Revolade 50mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby. warnings Driving UNSAFE Revolade 50mg Tablet may cause side effects which could affect your ability to drive.

Product Details:

Jaknat (Tofacitinib 5 mg) can lower the ability of your immune system to fight infections. Do not start taking Jaknat  if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking Jaknat . These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with Jaknat .
Before and after starting Jaknat , tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of Jaknat /Jaknat  XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is Jaknat  5 mg twice daily or Jaknat  XR 11 mg one time each day.
Cancer. Jaknat  may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of Jaknat  (10 mg twice daily) or Jaknat  XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken Jaknat  with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of Jaknat /Jaknat  XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking Jaknat  and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Jaknat  can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using Jaknat  and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Sunitinib 12.5mg,25mg,50mg is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery.
†Sunitinib   is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC).
‡Sunitinib   is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation.
§Sunitinib   is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.It is not known if Sunitinib   is safe and effective in children.IMPORTANT SAFETY INFORMATIONSunitinib   can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with Sunitinib  :
itchingyellow eyes or skindark urinepain or discomfort in the right upper stomach areaYour healthcare provider should do blood tests to check your liver function before you start taking and during treatment with Sunitinib  . Your healthcare provider may tell you to temporarily or permanently stop taking Sunitinib   if you develop liver problems.
Sunitinib   may cause serious side effects, including:
Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with Sunitinib   if you have signs and symptoms of heart failure.Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with Sunitinib  . Tell your healthcare provider immediately if:
you feel faint or lightheaded, or you pass outyou feel dizzyyou feel your heart beat is irregular or fastHigh blood pressure. High blood pressure is common with Sunitinib   and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:
severe headachelightheadednessdizzinesschange in visionYour healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with Sunitinib   until your high blood pressure is controlled.
Bleeding problems. Bleeding is common with Sunitinib  , but Sunitinib   can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with Sunitinib  , including:
painful, swollen stomach (abdomen)vomiting bloodblack, sticky stoolsbloody urineheadache or change in your mental statuscoughing up blood

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Jakavi ( Ruxolitinib 5mg 10mg 20mg) Tablet is used in the treatment of chronic idiopathic myelofibrosis and Polycythemia vera.
Jakavi 5mg Tablet can be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.
Headache, dizziness, low platelet count are some common side effects of this medicine. This medicine may reduce the number of blood cells (decrease red blood) in your blood, thereby, increasing the susceptibility to infections. Regular blood tests are required to check your blood cells along with heart, liver, kidney and lipid levels.
Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

How Jakavi Tablet Works:

• Jakavi 5mg Tablet is an anti-cancer medication. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps to stop or slow the spread of cancer cells.

Consult Your Doctor:

• Jakavi 5mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.

Consult Your Doctor:

• Jakavi 5mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.

Warnings Driving Unsafe:

• Jakavi 5mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.

Caution:

• Jakavi 5mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Jakavi 5mg Tablet may be needed. Please consult your doctor. Use of Jakavi 5mg Tablet is not advised in patients with moderate to severe kidney disease.

Product Details:

Pomide (Pomalidomide 1mg,2mg,4mg) is a prescription medicine used to treat adults with:
Multiple myeloma. Pomide  is taken along with the medicine dexamethasone, in people who:have received at least 2 prior medicines to treat multiple myeloma, including a type of medicine known as a proteasome inhibitor and lenalidomide, andtheir disease has become worse during treatment or within 60 days of finishing the last treatmentAIDS-related Kaposi sarcoma (KS). Pomide  is taken when highly active antiretroviral therapy (HAART) has not worked well enough or stopped working (failed)KS who do not have HIV infection (HIV negative).It is not known if Pomide  is safe and effective in children.
Who should not take Pomide ?
Do not take Pomide  if you:
are pregnant, plan to become pregnant, or become pregnant during treatment with Pomide . See “What is the most important information I should know about Pomide ?”are allergic to pomalidomide or any of the ingredients in Pomide . See the end of this Medication Guide for a complete list of ingredients in Pomide .What are the possible side effects of Pomide ?
Pomide  can cause serious side effects, including:
Low white blood cells (neutropenia), low platelets (thrombocytopenia), and low red blood cells (anemia) arecommon with Pomide , but can also be serious. You may need a blood transfusion or certain medicines if your blood counts drop too low. Your blood counts should be checked weekly for the first 8 weeks of treatment and monthly after that.Severe liver problems, including liver failure and death. Your healthcare provider should do blood tests to check your liver function during your treatment with Pomide . Tell your healthcare provider right away if you develop any of the following symptoms of liver problems:Yellowing of your skin or the white part of your eyes (jaundice)Dark or brown (tea-colored) urinePain on the upper right side of your stomach area (abdomen)Bleeding or bruising more easily than normalFeeling very tiredSevere allergic reactions and severe skin reactions can happen with Pomide  and may cause death.Call your healthcare provider if you develop any of the following signs or symptoms during treatment with Pomide :
a red, itchy, skin rashpeeling of your skin or blisterssevere itchingfeverGet emergency medical help right away if you develop any of the following signs or symptoms during treatment with Pomide :
swelling of your lips, mouth, tongue, or throattrouble breathing or swallowingraised red areas on your skin (hives)a very fast heartbeatyou feel dizzy or faintDizziness and confusion. See “What should I avoid while taking Pomide ?Nerve damage. Stop taking Pomide  and call your healthcare provider if you develop symptoms of nerve damage including: numbness, tingling, pain, burning sensation in your hands, legs, or feet. Risk of new cancers (malignancies). New cancers, including certain blood cancers (acute myelogenous leukemia or AML) have been seen in people who received Pomide . Talk with your healthcare provider about your risk of developing new cancers if you take Pomide .Tumor lysis syndrome (TLS). TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.Your healthcare provider may tell you to stop taking Pomide  if you develop certain serious side effects during treatment.

Product Details:

TASIGNA (nilotinib 150mg,200mg) capsules is a prescription medicine used to treat: Adults with newly diagnosed Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phaseAdults with Ph+ CML in chronic phase IMPORTANT SAFETY INFORMATION ABOUT TASIGNA (nilotinib) Capsules
QTc Prolongation and Sudden Death: TASIGNA can cause QTc prolongation, a possibly life-threatening heart problem. QTc prolongation causes an irregular heartbeat, which may lead to sudden death. Call your doctor right away if you feel lightheaded, faint, or have an irregular heartbeat while taking TASIGNA. These can be symptoms of QTc prolongation.
Your doctor should check your heart with a test called an electrocardiogram (ECG)Do not take TASIGNA if you have long QTc syndrome or low levels of potassium or magnesium in your bloodTASIGNA can interact with many medicines and supplements. This may increase your chances for serious and life-threatening side effects. Do not take any other medicine while taking TASIGNA unless your doctor tells you it is okay to do soFood and grapefruit products increase the amount of TASIGNA in your body. This may increase your chances for serious and life-threatening side effects. Take TASIGNA on an empty stomachAvoid eating food for at least 2 hours before the dose is taken, and avoid eating food for at least 1 hour after the dose is takenAvoid grapefruit, grapefruit juice, and any supplement containing grapefruit extract while taking TASIGNATASIGNA can cause serious side effects that can even lead to death. During treatment with TASIGNA your doctor will do tests to check for side effects. These tests will check your heart, blood cells (white blood cells, red blood cells, and platelets), electrolytes (potassium, magnesium), cholesterol, blood sugar, and pancreas and liver function. Your doctor may have you stop TASIGNA for some time or lower your dose if you have side effects. You should follow your doctor’s instructions. Serious side effects include:
Low Blood Counts: Low blood counts are common with TASIGNA but can also be severe. Your doctor will check your blood counts regularly during treatment with TASIGNA. Call your doctor right away if you have symptoms of low blood counts including:Fever, chills, or other signs of infectionUnexplained bleeding or bruisingShortness of breathUnexplained weakness
Decreased Blood Flow to the Legs, Heart, or Brain: People who have recently been diagnosed with Ph+ CML and take TASIGNA may develop decreased blood flow to the legs, heart, or brain. Get medical help right away if you suddenly develop any of the following symptoms:Chest pain or discomfortNumbness or weaknessProblems walking or speakingLeg pain or your leg feels coldChange in the skin color of your leg
Pancreas Inflammation (Pancreatitis): Call your doctor if you have symptoms including sudden stomach area pain with nausea and vomiting

Liver Problems: TASIGNA can increase your risk of liver problems. People who have had liver problems in the past may be at risk for getting liver problems with TASIGNA. Call your doctor, or get medical help right away if you develop any symptoms of liver problems including stomach area (abdominal) pain, yellow skin/eyes, and dark-colored urine

Tumor Lysis Syndrome (TLS): TLS is caused by a fast breakdown of cancer cells. Your doctor may do blood tests to check you for TLS. TLS can cause you to have kidney failure (with the need for dialysis treatment) and/or an abnormal heartbeat

Bleeding Problems: Serious bleeding problems and death have happened during treatment with TASIGNA. Call your doctor right away if you develop signs and symptoms of bleeding such as uncontrolled bleeding, changes in eyesight, unconsciousness, sudden headache, or sudden confusion about your surroundings.

Product Details:

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat various types of non-Hodgkin lymphoma, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL). It may be used both in relapsed as well as in treatment-naive settings.

Common side effects include headaches, feeling tired, low red blood cells, low platelets, and low white blood cells. Acalabrutinib is a second generation Bruton's tyrosine kinase inhibitor. Acalabrutinib blocks an enzyme called Bruton's tyrosine kinase, which helps B cells to survive and grow. By blocking this enzyme, acalabrutinib is expected to slow down the build-up of cancerous B cells in CLL, thereby delaying progression of the cancer.

Acalabrutinib was approved for medical use in the United States in 2017, and in the European Union in November 2020

The most common adverse events were headache, diarrhea and weight gain. Despite the appearance of a greater occurrence of transient headaches, data suggest a preferred advantage of acalabrutinib over ibrutinib due to expected reduced adverse events of skin rash, severe diarrhea, and bleeding risk.

Product Details:

Selpercatinib 80mg is a prescription medicine that is used to treat certain cancers caused by abnormal RET genes in adults with non-small cell lung cancer (NSCLC) that has spread, adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread who require a medicine by mouth or injection (systemic therapy), and adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread who require a medicine by mouth or injection (systemic therapy) and who have received radioactive iodine and it did not work or is no longer working.
Your healthcare provider will perform a test to make sure that Selpercatinibis right for you. It is not known if Selpercatinibis safe and effective in children younger than 12 years of age.
Selpercatinibwas approved based on the percentage of patients whose tumor size shrank or disappeared after treatment and how long the response lasted. Studies are ongoing to confirm the benefit of Selpercatinibfor this use.
Selpercatinibmay affect both healthy cells and tumor cells, which can result in side effects, some of which can be serious.Important Facts About RETEVMO® (reh-TEHV-moh). It is also known as selpercatinib.
Selpercatinibis a prescription medicine that is used to treat certain cancers caused by an abnormal gene, called RET, in:
adults with non-small cell lung cancer (NSCLC) that has spread.adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who need a medicine that can be taken by mouth or injection.adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread, who need a medicine that can be taken by mouth or injection, and who have received radioactive iodine and it did not work or is no longer working.Your doctor will perform a test to make sure that Selpercatinibis right for you.
It is not known if Selpercatinibis safe and effective in children younger than 12 years of age.
Warnings
Selpercatinibmay cause serious side effects, including:
Liver problems: Liver problems (higher levels of liver enzymes) are common with Selpercatiniband may sometimes be serious. Your doctor will do blood tests before and during treatment with Selpercatinibto check for liver problems. Tell your doctor right away if you get any of the following symptoms of liver problems during treatment:
yellowing of your skin or the white part of your eyes (jaundice)dark, “tea-colored” urinesleepinessbleeding or bruisingloss of appetitenausea or vomitingpain on the upper right side of your stomach areaIf you develop liver problems while taking RETEVMO, your doctor may lower your dose, stop treatment for a while, or stop treatment permanently.
High blood pressure (hypertension): High blood pressure is common with Selpercatinib  It may sometimes be serious. You should check your blood pressure regularly during treatment with Selpercatinib  Tell your doctor if you get any of the following symptoms during treatment:
confusionheadachesshortness of breathdizzinesschest painHeart rhythm changes (QT prolongation) can happen. These may be serious. Selpercatinibmay cause very slow, very fast, or irregular heartbeats. Tell your doctor right away if you get any of the following symptoms during treatment:
loss of consciousnessfaintingdizzinessa change in the way your heart beats (heart palpitations)Bleeding problems: Selpercatinibcan cause bleeding, which can be serious and may lead to death. 

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Erivedge (Vismodegib 150mg) capsule is a prescription medicine used to treat adults with a type of skin cancer, called basal cell carcinoma, that has spread to other parts of the body or that has come back after surgery or that your healthcare provider decides cannot be treated with surgery or radiation. It is not known if Erivedge is safe and effective in children. Important Safety Information What is the most important information I should know about Erivedge? Erivedge can cause your baby to die before it is born (be stillborn) or cause your baby to have severe birth defects. For females who can become pregnant: You should talk with your healthcare provider about the risks of Erivedge to your unborn child Your healthcare provider will do a pregnancy test within 7 days before you start taking Erivedge In order to avoid pregnancy, you should use birth control during treatment and for 24 months after your final dose of Erivedge. Talk with your healthcare provider about what birth control method is right for you during this time Talk to your healthcare provider right away if you have unprotected sex or if you think that your birth control has failed Tell your healthcare provider right away if you become pregnant or think that you may be pregnant For males: Erivedge is present in semen. Do not donate semen while you are taking Erivedge and for 3 months after your final dose You should always use a condom, even if you have had a vasectomy, during sex with female partners who are pregnant or who are able to become pregnant, during treatment with Erivedge, and for 3 months after your final dose to protect your female partner from being exposed to Erivedge Tell your healthcare provider right away if your partner becomes pregnant or thinks she is pregnant while you are taking Erivedge Pregnancy Exposure Registry: There is a Pregnancy Exposure Registry for females taking Erivedge who become pregnant. The purpose of this registry is to monitor the health of you and your unborn baby. If you think that you or your female partner may have been exposed to Erivedge during pregnancy, talk to your healthcare provider right away. If you become pregnant during treatment with Erivedge, you or your healthcare provider should report your pregnancy to Genentech at (888) 835-2555. What should I tell my healthcare provider before taking Erivedge? If you are pregnant or plan to become pregnant If you are breastfeeding or plan to breastfeed. It is not known if Erivedge passes into your breast milk. You should not breastfeed during treatment and for 24 months after your final dose of Erivedge. Talk to your healthcare provider about the best way to feed your baby during this time About all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements What should I avoid while taking Erivedge? Do not donate blood or blood products while you are taking Erivedge and for 24 months after your final dose Do not donate semen while you are taking Erivedge and for 3 months after your final dose What are the possible side effects of Erivedge? Serious skin reactions: Severe skin reactions have happened in some people taking Erivedge. You may need to be treated in a hospital because these severe skin reactions can be life-threatening or lead to death. Tell your healthcare provider right away if you develop any of the following signs or symptoms of a severe skin reaction, including: Blisters or peeling of your skin Blisters on your lip, or around your mouth or eyes Mouth sores or genital sores High fever or flu-like symptoms Enlarged lymph nodes Skin pain and burning Your healthcare provider may permanently stop Erivedge if you develop a severe skin reaction.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Midostaurin 25mg  is a brand-name prescription medication. It’s approved to treat the following conditions in adults:  Newly diagnosed acute myeloid leukemia (AML) in people with a certain genetic mutation. AML is a type of cancer that’s found in your blood and bone marrow. Midostaurin is given to people with AML who have an abnormal (mutated) FLT3 gene. For this use, Midostaurin is used in combination with chemotherapy drugs. Certain types of systemic mastocytosis. This condition affects certain blood cells called mast cells. In some cases, it can lead to blood cancer. Midostaurin can be used alone to treat the following types of systemic mastocytosis: aggressive systemic mastocytosis (ASM) systemic mastocytosis that occurs with a form of cancer called associated hematological neoplasm (SM-AHN) mast cell leukemia (MCL), which is a type of cancer that may develop from ASM Midostaurin comes as capsules that are taken by mouth twice daily. It contains the drug midostaurin, which belongs to a class of drugs called kinase inhibitors. (A class of drugs describes medications that work in the same way.)  Midostaurin isn’t considered a chemotherapy drug. Chemotherapy refers to traditional drugs used to treat cancer. These drugs typically affect both cancer cells and normal cells in your body. Midostaurin , on the other hand, is a targeted drug. It’s designed to work mainly on cancer cells.  FDA approval In 2017, the Food and Drug Administration (FDA) approved Midostaurin for use. It was the first targeted therapy drug approved to treat AML.  Effectiveness In a clinical study, Midostaurin was effective in treating AML. People in this study were given either Midostaurin or a placebo (treatment with no active drug). Both groups of people were also given chemotherapy drugs. The results showed the following:  People taking Midostaurin were 23% more likely to still be alive after at least 3.5 years than were people taking the placebo. About 50% of the people taking Midostaurin went at least 8 months without having certain complications caused by their cancer. In comparison, about 50% of people taking the placebo went at least 3 months without having certain complications caused by their cancer. In another clinical study, Midostaurin was effective in treating certain types of systemic mastocytosis. In this study, 21% of people taking Midostaurin alone had complete remission* or partial remission.** These results were reported after six cycles of treatment. (The length of these treatment cycles varied.)  * With complete remission, the people had an absence of mutated (abnormal) mast cells.  ** With partial remission, the people had reduced activity of mutated mast cells.  Midostaurin generic Midostaurin is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand-name medication.  Midostaurin contains the active ingredient midostaurin.  Midostaurin cost As with all medications, the cost of Midostaurin can vary.  The actual price you’ll pay depends on your insurance plan, your location, and the pharmacy you use.  Your insurance plan may require you to get prior authorization before approving coverage for Midostaurin . This means that your doctor and insurance company will need to communicate about your prescription before the insurance company will cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Midostaurin .  If you’re not sure if you’ll need to get prior authorization for Midostaurin , contact your insurance company. 

Product Details:

Erlotinib 150mg a kinase inhibitor, is a quinazolinamine with the chemical name N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)4-quinazolinamine. Erlotinib hydrochloride has the molecular formula C22H23N3O4.HCl and a molecular weight of 429.90. The molecule has a pKa of 5.42 at 25°C. Erlotinib hydrochloride is very slightly soluble in water, slightly soluble in methanol and practically insoluble in acetonitrile, acetone, ethyl acetate and hexane.  Aqueous solubility of erlotinib hydrochloride is dependent on pH with increased solubility at a pH of less than 5 due to protonation of the secondary amine. Over the pH range of 1.4 to 9.6, maximal solubility of approximately 0.4 mg/mL occurs at a pH of approximately 2.  Erlotinib  tablets for oral administration are available in three dosage strengths containing erlotinib hydrochloride (27.3 mg, 109.3 mg and 163.9 mg) equivalent to 25 mg, 100 mg and 150 mg erlotinib and the following inactive ingredients: lactose monohydrate, hypromellose, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate and titanium dioxide. The tablets also contain trace amounts of color additives, including FD&C Yellow 6 (25 mg only) for product identification. INDICATIONS Non-Small Cell Lung Cancer (NSCLC) Erlotinib ® Is Indicated For The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen [see Clinical Studies]. Limitations Of Use Safety and efficacy of Erlotinib  have not been established in patients with NSCLC whose tumors have other EGFR mutations [see Clinical Studies]. Erlotinib  is not recommended for use in combination with platinum-based chemotherapy [see Clinical Studies]. DOSAGE AND ADMINISTRATION Selection of Patients with Metastatic NSCLC Select patients for the treatment of metastatic NSCLC with Erlotinib  based on the presence of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations in tumor or plasma specimens [See Clinical Studies]. If these mutations are not detected in a plasma specimen, test tumor tissue if available. Information on FDA-approved tests for the detection of EGFR mutations in NSCLC is available at: Recommended Dose - NSCLC The recommended daily dose of Erlotinib  for NSCLC is 150 mg taken on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.

Product Details:

CUCHEL (Trientine Hydrochloride 250mg) CAPSULE is used to treat a certain inherited disorder (Wilson's disease). This disorder causes too much copper to build up in the liver, brain, and other parts of the body. Trientine works by binding to copper, which helps your body get rid of extra copper. This can decrease symptoms such as problems with speech/swallowing/coordination, tiredness, lack of appetite, abdominal pain, yellowing eyes/skin, fluid buildup in the legs/abdomen, uncontrolled movements, or muscle stiffness. Doctors typically use blood tests and a 24-hour urine collection test to diagnose Wilson disease. Doctors may also use a liver biopsy and imaging tests. For a blood test, a health care professional will take a blood sample from you and send the sample to a lab. There is no cure for Wilson disease. Lifelong treatment is necessary and could include: Taking copper-chelating medications, which help your body's organs and tissues get rid of excess copper. Reducing the amount of copper you get through food.Wilson's disease is a rare inherited disorder that causes copper to accumulate in your liver, brain and other vital organs. Most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well.Filing for Social Security Disability with a Wilson's Disease Diagnosis. Wilson's disease is listed in the Social Security Administration's (SSA) impairment listing manual (more commonly called the “Blue Book”) as one of the conditions which may qualify a person to receive Social Security Disability benefits.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

SUTENT (Sunitinib 12.5mg,25mg,50mg) is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery. †SUTENT is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC). ‡SUTENT is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation. §SUTENT is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery. It is not known if SUTENT is safe and effective in children. IMPORTANT SAFETY INFORMATION SUTENT can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with SUTENT: itching yellow eyes or skin dark urine pain or discomfort in the right upper stomach area Your healthcare provider should do blood tests to check your liver function before you start taking and during treatment with SUTENT. Your healthcare provider may tell you to temporarily or permanently stop taking SUTENT if you develop liver problems. SUTENT may cause serious side effects, including: Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with SUTENT if you have signs and symptoms of heart failure. Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with SUTENT. Tell your healthcare provider immediately if: you feel faint or lightheaded, or you pass out you feel dizzy you feel your heart beat is irregular or fast High blood pressure. High blood pressure is common with SUTENT and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure: severe headache lightheadedness dizziness change in vision Your healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with SUTENT until your high blood pressure is controlled.

Product Details:

Rcnet (Sunitinib 12.5mg,25mg,50mg) is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery.
†Rcnet  is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC).
‡Rcnet  is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation.
§Rcnet  is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.It is not known if Rcnet  is safe and effective in children.IMPORTANT SAFETY INFORMATIONRcnet  can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with Rcnet :
itchingyellow eyes or skindark urinepain or discomfort in the right upper stomach areaYour healthcare provider should do blood tests to check your liver function before you start taking and during treatment with Rcnet . Your healthcare provider may tell you to temporarily or permanently stop taking Rcnet  if you develop liver problems.
Rcnet  may cause serious side effects, including:
Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with Rcnet  if you have signs and symptoms of heart failure.Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with Rcnet . Tell your healthcare provider immediately if:
you feel faint or lightheaded, or you pass outyou feel dizzyyou feel your heart beat is irregular or fastHigh blood pressure. High blood pressure is common with Rcnet  and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:
severe headachelightheadednessdizzinesschange in visionYour healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with Rcnet  until your high blood pressure is controlled.
Bleeding problems. Bleeding is common with Rcnet , but Rcnet  can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with Rcnet , including:
painful, swollen stomach (abdomen)vomiting bloodblack, sticky stoolsbloody urineheadache or change in your mental statuscoughing up bloodYour healthcare provider:
can tell you about other symptoms to watch formay do blood tests if needed and monitor you for bleedingSerious stomach and intestinal problems that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation) or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with Rcnet .

Product Details:

Sutekast (Sunitinib 12.5mg,25mg,50mg) is used to treat adults with kidney cancer that has not spread (localized) and who are at high risk of RCC coming back again after having kidney surgery.
†Sutekast is used to treat advanced kidney cancer (advanced renal cell carcinoma or RCC).
‡Sutekast is used to treat a rare cancer of the stomach, bowel, or esophagus called gastrointestinal stromal tumor (GIST) and when you have taken the medicine imatinib mesylate (Gleevec®) and it did not stop the cancer from growing or you cannot take imatinib mesylate (Gleevec®). Gleevec is a registered trademark of Novartis Pharmaceuticals Corporation.
§Sutekast is used to treat a type of pancreatic cancer known as pancreatic neuroendocrine tumors (pNET) that has progressed and cannot be treated with surgery.It is not known if Sutekast is safe and effective in children.IMPORTANT SAFETY INFORMATIONSutekast can cause severe liver problems that can lead to death. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems during treatment with Sutekast:
itchingyellow eyes or skindark urinepain or discomfort in the right upper stomach areaYour healthcare provider should do blood tests to check your liver function before you start taking and during treatment with Sutekast. Your healthcare provider may tell you to temporarily or permanently stop taking Sutekast if you develop liver problems.
Sutekast may cause serious side effects, including:
Heart problems. Heart problems may include heart failure, heart attack and heart muscle problems (cardiomyopathy) that can lead to death. Tell your healthcare provider if you feel very tired, are short of breath, or have swollen feet and ankles. Your healthcare provider may stop your treatment with Sutekast if you have signs and symptoms of heart failure.Abnormal heart rhythm changes. Changes in the electrical activity of your heart called QT prolongation can cause irregular heartbeats that can be life threatening. Your healthcare provider may do electrocardiograms and blood tests (electrolytes) to watch for these problems during your treatment with Sutekast. Tell your healthcare provider immediately if:
you feel faint or lightheaded, or you pass outyou feel dizzyyou feel your heart beat is irregular or fastHigh blood pressure. High blood pressure is common with Sutekast and may sometimes be severe. Follow your healthcare provider’s instructions about having your blood pressure checked regularly. Call your healthcare provider if your blood pressure is high or if you have any of the following signs or symptoms of high blood pressure:
severe headachelightheadednessdizzinesschange in visionYour healthcare provider may prescribe medicine for you to treat high blood pressure, if needed. Your healthcare provider may temporarily stop your treatment with Sutekast until your high blood pressure is controlled.
Bleeding problems. Bleeding is common with Sutekast, but Sutekast can also cause severe bleeding problems that can lead to death. Call your healthcare provider right away if you have any of these symptoms or a serious bleeding problem during treatment with Sutekast, including:
painful, swollen stomach (abdomen)vomiting bloodblack, sticky stoolsbloody urineheadache or change in your mental statuscoughing up bloodYour healthcare provider:
can tell you about other symptoms to watch formay do blood tests if needed and monitor you for bleedingSerious stomach and intestinal problems that can sometimes lead to death. Some people have had tears in their stomach or intestine (perforation) or have developed an abnormal opening between the stomach and intestine (fistula). Get medical help right away if you get stomach-area (abdominal) pain that does not go away or is severe during treatment with Sutekast.

Product Details:

Acalabrutinib 100mg is the generic name for the trade name drug Acalabrutinib . In some cases, health care professionals may use the trade name Acalabrutinib  when referring to the generic drug name acalabrutinib.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

Rydapt (Midostaurin 25mg) is a brand-name prescription medication. It’s approved to treat the following conditions in adults: Newly diagnosed acute myeloid leukemia (AML) in people with a certain genetic mutation. AML is a type of cancer that’s found in your blood and bone marrow. Rydapt is given to people with AML who have an abnormal (mutated) FLT3 gene. For this use, Rydapt is used in combination with chemotherapy drugs. Certain types of systemic mastocytosis. This condition affects certain blood cells called mast cells. In some cases, it can lead to blood cancer. Rydapt can be used alone to treat the following types of systemic mastocytosis: aggressive systemic mastocytosis (ASM) systemic mastocytosis that occurs with a form of cancer called associated hematological neoplasm (SM-AHN) mast cell leukemia (MCL), which is a type of cancer that may develop from ASM Rydapt comes as capsules that are taken by mouth twice daily. It contains the drug midostaurin, which belongs to a class of drugs called kinase inhibitors. (A class of drugs describes medications that work in the same way.) Rydapt isn’t considered a chemotherapy drug. Chemotherapy refers to traditional drugs used to treat cancer. These drugs typically affect both cancer cells and normal cells in your body. Rydapt, on the other hand, is a targeted drug. It’s designed to work mainly on cancer cells. FDA approval In 2017, the Food and Drug Administration (FDA) approved Rydapt for use. It was the first targeted therapy drug approved to treat AML. Effectiveness In a clinical study, Rydapt was effective in treating AML. People in this study were given either Rydapt or a placebo (treatment with no active drug). Both groups of people were also given chemotherapy drugs. The results showed the following: People taking Rydapt were 23% more likely to still be alive after at least 3.5 years than were people taking the placebo. About 50% of the people taking Rydapt went at least 8 months without having certain complications caused by their cancer. In comparison, about 50% of people taking the placebo went at least 3 months without having certain complications caused by their cancer. In another clinical study, Rydapt was effective in treating certain types of systemic mastocytosis. In this study, 21% of people taking Rydapt alone had complete remission* or partial remission.** These results were reported after six cycles of treatment. (The length of these treatment cycles varied.) * With complete remission, the people had an absence of mutated (abnormal) mast cells. ** With partial remission, the people had reduced activity of mutated mast cells. Rydapt generic Rydapt is available only as a brand-name medication. It’s not currently available in generic form. A generic drug is an exact copy of the active drug in a brand-name medication. Rydapt contains the active ingredient midostaurin. Rydapt cost As with all medications, the cost of Rydapt can vary. The actual price you’ll pay depends on your insurance plan, your location, and the pharmacy you use. Your insurance plan may require you to get prior authorization before approving coverage for Rydapt. This means that your doctor and insurance company will need to communicate about your prescription before the insurance company will cover the drug. The insurance company will review the request and let you and your doctor know if your plan will cover Rydapt. If you’re not sure if you’ll need to get prior authorization for Rydapt, contact your insurance company. .

Product Details:

Tofacitinib 5 mg can lower the ability of your immune system to fight infections. Do not start taking Tofacitinib if you have any kind of infection unless your healthcare provider tells you it is okay. Serious Infections have happened in people taking Tofacitinib. These serious infections include tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should test you for TB before starting and during treatment with Tofacitinib.
Before and after starting Tofacitinib, tell your doctor if you have an infection or symptoms of an infection, including:
Fever, sweating, or chillsCoughBlood in phlegmWarm, red, or painful skin or sores on your bodyBurning when you urinateUrinating more often than normalMuscle achesShortness of breathWeight lossDiarrhea or stomach painFeeling very tiredIncreased risk of death in people 50 years of age and older with rheumatoid arthritis who have at least 1 heart disease (cardiovascular) risk factor and who are taking a higher than recommended dose of Tofacitinib/Tofacitinib XR. The recommended dose in patients with rheumatoid arthritis and psoriatic arthritis is Tofacitinib 5 mg twice daily or Tofacitinib XR 11 mg one time each day.
Cancer. Tofacitinib may increase your risk of certain cancers by changing the way your immune system works. Lymphoma and other cancers, including skin cancers, can happen. Tell your healthcare provider if you have ever had any type of cancer.
Higher dose.  People taking the higher dose of Tofacitinib (10 mg twice daily) or Tofacitinib XR (22 mg one time each day) have a higher risk of serious infections, shingles, or skin cancers.
Immune System Problem. Some people who have taken Tofacitinib with certain other medicines to prevent kidney transplant rejection have had a problem with certain white blood cells growing out of control (Epstein Barr Virus–associated post-transplant lymphoproliferative disorder).
Blood clots in the lungs (pulmonary embolism, PE), veins of the legs (deep vein thrombosis, DVT) and arteries (arterial thrombosis) have happened more often in patients with rheumatoid arthritis who are 50 years of age and older and with at least 1 heart disease (cardiovascular) risk factor taking a higher than recommended dose of Tofacitinib/Tofacitinib XR. Blood clots in the lungs have also happened in patients with ulcerative colitis. Some people have died from these blood clots.
• Stop taking Tofacitinib and tell your healthcare provider right away if you have any signs and symptoms of blood clots such as sudden shortness of breath, difficulty breathing, chest pain, swelling of a leg or arm, leg pain or tenderness, or red or discolored skin in the leg or arm.
Tears (perforation) in the stomach or intestines. Tell your healthcare provider if you have had diverticulitis (inflammation in parts of the large intestine) or ulcers in your stomach or intestines. Some people taking Tofacitinib can get tears in their stomach or intestine. This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Tell your healthcare provider right away if you have fever, stomach-area pain that does not go away, and a change in your bowel habits.
Serious allergic reactions can occur. Stop using Tofacitinib and call your healthcare provider right away if you have swelling of your lips, tongue, throat, or get hives.

Product Details:

Spexib (Ceritinib 150mg) Capsule is used in the treatment of non-small cell lung cancer. It shows its working by stopping or slowing down the growth of cancer cells.

Spexib Capsule should be taken with or without food, but try to have it at the same time every day to get the most benefits. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to.

Fatigue, nausea, vomiting, and diarrhea are some common side effects of this medicine. Some serious side effects that might occur which need doctor consultation include tiredness, itchy skin, yellowing of your skin, and chest pain or discomfort, changes in your heartbeat. Your doctor may perform some blood tests before and after the treatment to check for liver, or blood sugar level.

Before taking it, tell your doctor if you have heart disease, liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your healthcare team know all medications you are using. This medicine is not recommended during pregnancy or while breastfeeding. The use of effective contraception by both males and females during treatment is important to avoid pregnancy.

Disclaimer:

• Trademark shown are property of their respective owners and we do not lay any claim on them.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.

Product Details:

ZYKADIA (Cerinib 150mg) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that: Is caused by a defect in a gene called anaplastic lymphoma kinase (ALK) and has spread to other parts of the body It is not known if ZYKADIA is safe and effective in children. IMPORTANT SAFETY INFORMATION ABOUT ZYKADIA What is the most important information I should know about ZYKADIA? ZYKADIA may cause serious side effects, such as: Stomach and intestinal (gastrointestinal) problems ZYKADIA may cause stomach and intestinal problems, including diarrhea, nausea, vomiting, and stomach-area pain. Follow your health care provider’s instructions about taking medicines to help with these symptoms. Call your health care provider for advice if your symptoms are severe or cannot be tolerated Liver problems ZYKADIA may cause liver injury. Your health care provider should perform blood tests at least every month to check your liver during treatment with ZYKADIA. Tell your health care provider right away if you experience any of the following symptoms: You feel tired Your skin or the whites of your eyes turn yellow You have a decreased appetite Your urine turns dark or brown (tea color) You have itchy skin You have nausea or vomiting You have pain on the right side of your stomach area You bleed or bruise more easily than normal Lung problems (pneumonitis) ZYKADIA may cause severe or life-threatening swelling (inflammation) of the lungs during treatment that can lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your health care provider right away if you have any new or worsening symptoms, including: Trouble breathing or shortness of breath Cough, with or without mucus Fever Chest pain Heart problems ZYKADIA may cause very slow, very fast, or abnormal heartbeats. Your health care provider may check your heart during treatment with ZYKADIA. Tell your health care provider right away if you feel new chest pain or discomfort, dizziness or lightheadedness, faint, or have abnormal heartbeats. Tell your health care provider if you start to take or have any changes in heart or blood pressure medicines High blood sugar (hyperglycemia) People who have diabetes or glucose intolerance or those who take a corticosteroid medicine have an increased risk of high blood sugar with ZYKADIA. Your health care provider will check your blood sugar level before starting ZYKADIA and as needed during treatment with ZYKADIA. Call your health care provider right away if you have any symptoms of high blood sugar, including: Increased thirst Urinating often Increased hunger Blurred vision Headaches Tiredness Trouble thinking or concentrating Your breath smells like fruit Inflammation of the pancreas (pancreatitis) ZYKADIA can cause pancreatitis that has led to death. You may develop increased pancreatic enzyme blood levels, which may be a sign of pancreatitis. Signs and symptoms of pancreatitis include upper abdominal pain that may spread to the back and get worse with eating. Your health care provider should perform blood tests to check your pancreatic enzyme blood levels before you start ZYKADIA and as needed during your treatment Before you take ZYKADIA, tell your health care provider about all of your medical conditions, including if you: have liver problems have diabetes or high blood sugar have heart problems, including a condition called long QT syndrome have or have had pancreatitis are pregnant or plan to become pregnant. ZYKADIA can harm your unborn baby. Women who are able to become pregnant should use an effective method of birth control during treatment with ZYKADIA and for 6 months after stopping ZYKADIA. Talk to your health care provider about birth control methods that may be right for you. Tell your health care provider right away if you become pregnant or think that you may be pregnant.

Product Details:

Nivolumab 40mg,100mg is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.
Nivolumab is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.
Nivolumab (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous(IV) use.
For people with previously treated advanced non-small cell lung cancer
Nivolumab  (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.
For people with advanced melanoma
Nivolumab  (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).Nivolumab  (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).Nivolumab (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous(IV) use.
For people with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back
Nivolumab  (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.
For certain people with advanced kidney cancer (renal cell carcinoma)
Nivolumab  (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with kidney cancer in certain people when their cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC.
Nivolumab (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous(IV) use.
For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread
Nivolumab  (nivolumab) is a prescription medicine used in combination with cabozantinib to treat people with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.
For people with previously treated advanced kidney cancer (renal cell carcinoma)
Nivolumab  (nivolumab) is a prescription medicine used to treat people with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.
For people with previously treated squamous cell carcinoma of the head and neck
Nivolumab  (nivolumab) is a prescription medicine used to treat people with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.

Additional Information:

• Production Capacity: NA
• Delivery Time: Immediate
• Packaging Details: Trademark shown are property of their respective owners and we do not lay any claim on them. Parallel trade if any is conducted under WTO¿¿¿s TRIPS agreement to which India is a Signatory. On this page we have made an ¿¿¿Honest Reference¿¿¿ of this product under the Trademark Act of India and applicable rules in the Territory of India. We do not claim ownership of displayed Trade mark.